Related Experiment Video

Updated: Aug 13, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

[Regression of left ventricular hypertrophy in hypertensive patients]

F Bosa Ojeda1, M García González, A Domínguez Rodríguez

  • 1Servicio de Cardiología, Hospital Universitario de Canarias, Tenerife.

Revista Espanola De Cardiologia
|January 1, 1997
PubMed

Insights

Systemic hypertension causes left ventricular hypertrophy (LVH) through hemodynamic and biochemical factors. Antihypertensive drugs can reverse LVH, with angiotensin converting enzyme inhibitors showing particular potency.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Biomedical Science

Context:

  • Left ventricular hypertrophy (LVH) in systemic hypertension presents unique pathophysiological mechanisms compared to other pressure overload conditions.
  • LVH is strongly correlated with increased cardiovascular morbidity and mortality.
  • Reversal of LVH is a significant therapeutic objective in managing hypertension.

Purpose:

  • To review the literature on the effects of antihypertensive treatments on left ventricular mass.
  • To identify the most effective medication classes for LVH regression.
  • To explore the potential independent impact of LVH reversal on cardiovascular risk.

Summary:

  • Antihypertensive medications generally reduce left ventricular mass, but treatment duration varies.
  • Angiotensin converting enzyme inhibitors appear particularly effective due to their dual action: blood pressure reduction and blockade of angiotensin II's trophic effects.
  • The independent effect of antihypertensive treatment-induced LVH reversal on cardiovascular risk remains an open question.

Impact:

  • Provides a comprehensive overview of LVH regression strategies in hypertensive patients.
  • Highlights the potential superiority of angiotensin converting enzyme inhibitors in managing hypertensive heart disease.
  • Identifies a critical knowledge gap regarding the independent cardiovascular benefits of LVH reversal.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...